Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2015

Open Access 01-12-2015 | Original Article

Urinary nerve growth factor in patients with detrusor overactivity

Authors: A. Korzeniecka-Kozerska, A. Wasilewska

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2015

Login to get access

Abstract

Background

Detrusor overactivity (DO) is one of the most frequent bladder dysfunctions in children up to the age of 18. Nowadays, the only way to confirm DO is by urodynamic investigation, which is an invasive procedure. Among the many mediators influencing bladder function, nerve growth factor (NGF) plays an important role. The present study was designed to measure urinary NGF (uNGF) levels in patients with DO diagnosed by urodynamic study in comparison with healthy controls.

Methods

The investigation was conducted on 44 children, divided into two groups (24 patients with DO, 20 healthy children). Uroflowmetry was performed in all enrolled to the study and cystometry only to patients. uNGF levels were estimated in both studied groups.

Results

The median uNGF level in patients with DO before treatment was higher compared with healthy controls. There were no differences between uNGF levels in patients after anticholinergic treatment and the controls. We found differences in uroflowmetry parameters between the reference group and the patients. We found correlations between uroflowmetry parameters and uNGF/cr. level.

Conclusions

1.
The uNGF level could be used for detecting DO in children and adolescents.
 
2.
Measuring uNGF level is a simple, noninvasive procedure and very useful for choosing therapy in patients with DO in various clinical conditions.
 
Literature
1.
go back to reference de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharm 147(Suppl 2):S25–S40CrossRef de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharm 147(Suppl 2):S25–S40CrossRef
2.
go back to reference Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 102:1440–1444PubMed Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 102:1440–1444PubMed
3.
go back to reference Avlan D, Gundogdu G, Taskinlar H et al (2012) Relationship among vesicoureteric reflux, urinary tract infection and renal injury in children with non-neurogenic lower urinary tract dysfunction. J Pediatr Urol 7:612–615CrossRef Avlan D, Gundogdu G, Taskinlar H et al (2012) Relationship among vesicoureteric reflux, urinary tract infection and renal injury in children with non-neurogenic lower urinary tract dysfunction. J Pediatr Urol 7:612–615CrossRef
4.
go back to reference Foldspang A, Mommsen S (1994) Adult female urinary incontinence and childhood bedwetting. J Urol 152:85–88PubMed Foldspang A, Mommsen S (1994) Adult female urinary incontinence and childhood bedwetting. J Urol 152:85–88PubMed
5.
go back to reference Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270–2274CrossRefPubMed Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270–2274CrossRefPubMed
6.
go back to reference Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin A injection. Eur Urol 2533:1–8 Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin A injection. Eur Urol 2533:1–8
7.
8.
go back to reference Tanner R, Chambers P, Khadra MH et al (2000) The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 85:1115–1119CrossRefPubMed Tanner R, Chambers P, Khadra MH et al (2000) The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 85:1115–1119CrossRefPubMed
9.
go back to reference Steers WB (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4:7–18 Steers WB (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4:7–18
10.
go back to reference Lommatzsch NA, Braun A, Mannsfekr A et al (1999) Abundant production of brain derived neurotrophic factor by adult visceral epithelia: implications for paracrine and target-derived neurotrophic function. Am J Pathol 155:1183–1193PubMedCentralCrossRefPubMed Lommatzsch NA, Braun A, Mannsfekr A et al (1999) Abundant production of brain derived neurotrophic factor by adult visceral epithelia: implications for paracrine and target-derived neurotrophic function. Am J Pathol 155:1183–1193PubMedCentralCrossRefPubMed
11.
go back to reference Liu HT, Kuo HC (2008) Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. J Urol 72:104–108CrossRef Liu HT, Kuo HC (2008) Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. J Urol 72:104–108CrossRef
12.
go back to reference Liang CC, Tseng LH, Ko YS et al (2012) Expression of nerve growth factor immunoreactivity and messenger RNA in ischemic urinary bladder. Neurourol Urodyn 29:512–516 Liang CC, Tseng LH, Ko YS et al (2012) Expression of nerve growth factor immunoreactivity and messenger RNA in ischemic urinary bladder. Neurourol Urodyn 29:512–516
13.
go back to reference Jang J, Park EY, Seo SI et al (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435–439CrossRefPubMed Jang J, Park EY, Seo SI et al (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435–439CrossRefPubMed
14.
go back to reference Kim JC, Park EY, Seo SI et al (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder syndrome. J Urol 12:875–880 Kim JC, Park EY, Seo SI et al (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder syndrome. J Urol 12:875–880
15.
go back to reference Liu HT, Tyagi P, Chancellor MB et al (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685CrossRefPubMed Liu HT, Tyagi P, Chancellor MB et al (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685CrossRefPubMed
16.
go back to reference Liu HT, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodynam 28:78–81CrossRef Liu HT, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodynam 28:78–81CrossRef
17.
go back to reference Liu HT, Chancellor MB, Kuo HC (2009) Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 103:1668–1672CrossRefPubMed Liu HT, Chancellor MB, Kuo HC (2009) Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 103:1668–1672CrossRefPubMed
18.
go back to reference Kuo HC, Liu HT, Chancellor MB (2009) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodynam 29:482–487 Kuo HC, Liu HT, Chancellor MB (2009) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodynam 29:482–487
19.
go back to reference Oktar T, Kocak T, Oner-Iyidogan Y et al (2013) Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker. J Pediatr Urol 9(5):617–621CrossRefPubMed Oktar T, Kocak T, Oner-Iyidogan Y et al (2013) Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker. J Pediatr Urol 9(5):617–621CrossRefPubMed
20.
go back to reference Bright E, Oelke M, Tubaro A et al (2012) Ultrasound estimates bladder weight and measurement of bladder wall thickness-useful noninvasive methods for assessing the lower urinary tract? J Urol 184:1847–1854CrossRef Bright E, Oelke M, Tubaro A et al (2012) Ultrasound estimates bladder weight and measurement of bladder wall thickness-useful noninvasive methods for assessing the lower urinary tract? J Urol 184:1847–1854CrossRef
21.
go back to reference Hubeaux K, Deffeux X, Ismael SS et al (2007) Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactivity bladder syndrome or stress urinary incontinence. J Urol 178:2483–2487CrossRefPubMed Hubeaux K, Deffeux X, Ismael SS et al (2007) Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactivity bladder syndrome or stress urinary incontinence. J Urol 178:2483–2487CrossRefPubMed
22.
go back to reference Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodynam 27:417–420CrossRef Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodynam 27:417–420CrossRef
23.
go back to reference Korzeniecka-Kozerska A, Porowski T, Michaluk-Skutnik J et al (2013) Urinary nerve growth factor level in children with neurogenic bladder due to myelomeningocele. Scand J Urol 47(5):411–417CrossRefPubMed Korzeniecka-Kozerska A, Porowski T, Michaluk-Skutnik J et al (2013) Urinary nerve growth factor level in children with neurogenic bladder due to myelomeningocele. Scand J Urol 47(5):411–417CrossRefPubMed
24.
go back to reference Vijaya G, Cartwright R, Derpapas A et al (2013) Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J 24(9):1523–1528CrossRefPubMed Vijaya G, Cartwright R, Derpapas A et al (2013) Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J 24(9):1523–1528CrossRefPubMed
25.
go back to reference Starkman JS, Dmochowski RR (2008) Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodynam 27:13–21CrossRef Starkman JS, Dmochowski RR (2008) Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodynam 27:13–21CrossRef
26.
go back to reference Finney SM, Andersson KE, Gillespie JI et al (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor and sensory actions? BJU Int 98:503–507CrossRefPubMed Finney SM, Andersson KE, Gillespie JI et al (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor and sensory actions? BJU Int 98:503–507CrossRefPubMed
Metadata
Title
Urinary nerve growth factor in patients with detrusor overactivity
Authors
A. Korzeniecka-Kozerska
A. Wasilewska
Publication date
01-12-2015
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2015
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-014-1162-8

Other articles of this Issue 4/2015

Irish Journal of Medical Science (1971 -) 4/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.